Compare iShares MSCI Malaysia ETF (EWM) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Malaysia ETF vs Globus Medical Inc. Class A Common Stock — how do they compare? iShares MSCI Malaysia ETF trades at $26.86 (market cap $241.37M), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 42.5× iShares MSCI Malaysia ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI Malaysia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Malaysia ETF for 68 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| EWM | GMED | |
|---|---|---|
Market Cap | $241.37M | $10.25B |
Volume | 74,129 | 1,108,124 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $96.82 |
52-Week Low | $25.47 | $58.33 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | — | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWM trades at $26.96, up 0.63% today, but technical indicators signal a bearish trend with moving averages and ADX suggesting selling pressure. Key financial ratios like P/E and P/S are unavailable, limiting fundamental clarity. Recent news highlights external risks, such as regional haze-related disruptions affecting operations in Malaysia, which could impact investor confidence.
The outlook remains cautious due to weak technicals and limited fundamental data. Risks include environmental disruptions and market volatility. Investment opportunities hinge on upcoming financial disclosures to validate growth prospects, while current sentiment leans bearish amid uncertainty.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
